GHRP-2

Overview

GHRP-2 (Growth Hormone Releasing Peptide-2), also known by its pharmaceutical name Pralmorelin, is a synthetic hexapeptide that functions as a potent growth hormone secretagogue and ghrelin receptor agonist. It was developed as a second-generation improvement upon GHRP-6, offering enhanced GH-releasing potency with a somewhat improved side-effect profile.

GHRP-2 holds a unique distinction among the growth hormone releasing peptides: it is the only GHRP to have received regulatory approval for clinical use, having been approved in Japan under the trade name GHRP Kaken 100 as a diagnostic agent for growth hormone deficiency. The Japanese approval, granted by the Pharmaceuticals and Medical Devices Agency (PMDA), validated the compound’s pharmacological activity and safety profile in clinical settings.

Among the GHRP family, GHRP-2 is considered the most potent GH releaser on a per-milligram basis. It stimulates GH secretion more robustly than GHRP-6 and with less appetite stimulation, though it shares the tendency to modestly elevate cortisol and prolactin at supraphysiological doses. GHRP-2 has been widely used as a research tool in endocrinology for over three decades to study the GH secretagogue receptor system and to probe GH axis function.

Mechanism of Action

GHRP-2 stimulates growth hormone release through a multi-level mechanism involving both the pituitary gland and the hypothalamus.

Ghrelin Receptor Agonism

GHRP-2 is a potent agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a), the endogenous ligand of which is ghrelin. Binding to GHS-R1a activates the Gq/11-phospholipase C signaling cascade, generating inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 mobilizes calcium from intracellular stores, while DAG activates protein kinase C. The resulting elevation in intracellular calcium triggers fusion of GH-containing secretory vesicles with the plasma membrane.

Somatostatin Antagonism

A distinctive feature of GHRP-2 is its functional antagonism of somatostatin signaling. While GHRP-2 does not directly bind somatostatin receptors, it reduces somatostatin tone through hypothalamic mechanisms. This effectively lifts the inhibitory brake on GH secretion, which explains why GHRPs can stimulate GH release even during periods of high somatostatin activity when GHRH alone is ineffective.

GHRH Synergy

GHRP-2 and GHRH act through complementary intracellular pathways in somatotrophs. GHRH activates adenylyl cyclase and the cAMP-PKA pathway, while GHRP-2 activates the PLC-IP3-calcium pathway. When administered together, these agents produce synergistic GH release that exceeds the sum of their individual effects. This pharmacological synergy has been extensively documented in both animal and human studies.

Research Summary

Diagnostic Utility

Doi et al. (2004), publishing in the Journal of Clinical Endocrinology & Metabolism, evaluated GHRP-2 as a diagnostic tool for GH deficiency in Japanese adults. Intravenous administration of 100 mcg GHRP-2 reliably distinguished GH-deficient patients from healthy controls, with a sensitivity of 93% and specificity of 89% using a GH cutoff of 15 ng/mL. This study supported the regulatory approval of GHRP-2 as a diagnostic agent in Japan.

Comparative GH Secretagogue Studies

Bowers et al. (1994), in a seminal paper in the Journal of Clinical Endocrinology & Metabolism, compared the GH-releasing activity of GHRP-2, GHRP-6, and GHRH in healthy adults. GHRP-2 produced the highest peak GH levels (approximately 70-80 ng/mL at 1 mcg/kg IV) compared to GHRP-6 (approximately 40-60 ng/mL) and GHRH alone (approximately 20-30 ng/mL). The combination of GHRP-2 plus GHRH produced GH peaks exceeding 100 ng/mL in these studies.

Cortisol and Prolactin Effects

Arvat et al. (1997), publishing in the European Journal of Endocrinology, characterized the neuroendocrine profile of GHRP-2 in humans. At GH-stimulating doses (1 mcg/kg), GHRP-2 produced modest elevations in cortisol (approximately 30-50% above baseline) and prolactin (approximately 40-80% above baseline), both of which were transient and normalized within 2-3 hours. These effects were less pronounced than those of GHRP-6 at equipotent GH-releasing doses.

Age-Related GH Decline

Broglio et al. (2003), in European Journal of Endocrinology, investigated GHRP-2 in elderly subjects and found that while the absolute GH response was reduced compared to young adults (consistent with age-related somatopause), GHRP-2 still produced clinically meaningful GH elevations. The relative response to GHRP-2 was better preserved with aging than the response to GHRH alone, suggesting that the ghrelin pathway remains more functionally intact in older individuals.

Dosing in Published Research

GHRP-2, also known as pralmorelin, is a synthetic growth-hormone-releasing peptide. It is not approved in the United States. It is, however, approved in Japan as a diagnostic agent for assessing growth-hormone secretory capacity, where the labeled use is a single 100 microgram intravenous bolus, given as part of a GH-stimulation test in adults and children. That regimen was established in Japanese multicenter trials. These figures describe approved diagnostic use in Japan and the trials supporting it.

Safety and Side Effects

GHRP-2 has not been established as safe through completed clinical development. As a growth hormone secretagogue and ghrelin-receptor agonist it shares the class effects of fluid retention, altered insulin sensitivity and blood glucose, headache, and injection-site reactions, and it stimulates appetite, though generally less intensely than GHRP-6. It produces modest increases in cortisol and prolactin. Sustained elevation of growth hormone and IGF-1 carries the theoretical metabolic and proliferative concerns common to the class. Long-term human safety data do not exist, and research-chemical material is of uncertain identity and purity.

Current Research Status

GHRP-2 reached early clinical investigation, including use as a diagnostic agent for growth hormone secretion in some countries, but it is not approved by the FDA or as a therapeutic in major markets. It is prohibited in sport by the World Anti-Doping Agency. It is sold as a research chemical and should be regarded as investigational for any other purpose.

Frequently Asked Questions